- Artificial intelligence medical technology group Sensyne Health said it was exploring a potential dual-listing on Nasdaq, amongst other options, as part of a strategy update.

Sensyne Health said it continued to explore strategic opportunities, including making acquisitions.

'Any decision to list in the US would complement the company's primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company,' it said.

'Any acquisition or strategic equity partnership would be consistent with Sensyne's commitment to the ethical application of AI to patient data and its established strategic research agreements with the NHS and US health systems.'

Story provided by